John F. Seymour, MBBS, PhD

home / authors / john-f-seymour-mbbs-phd

Articles

Understanding the Mechanism and Sensitivity of BCL-2 Inhibitors

January 9th 2025

John Seymour, MBBS, FRACP, PhD, explains the mechanism of action of BCL-2 inhibitors like venetoclax.

Acalabrutinib Shows Better Exposure-Adjusted Tolerability in R/R CLL

John F. Seymour, MBBS, PhD

June 2nd 2022

John F. Seymour, MBBS, PhD, discusses the results of a post-hoc analysis of adverse events in the phase 3 ELEVATE-RR trial comparing acalabrutinib and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Rationale for In-Depth Analysis of BTK Inhibitor Tolerability in CLL

John F. Seymour, MBBS, PhD

April 29th 2022

John F. Seymour, MBBS, PhD, discusses the rationale for a post-hoc analysis of the phase 3 ELEVATE-RR trial comparing acalabrutinib and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Emerging Themes in Targeted Therapy Research for CLL

John F. Seymour, MBBS, PhD

February 11th 2019

John F. Seymour, MBBS, PhD, discusses some emerging themes from recent research for targeted therapies as treatment of patients with chronic lymphocytic leukemia.